A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors

Stopped After reviewing all available data from Part 1 of the trial, the Sponsor has decided not to proceed to Part 2 (randomized Phase 2) of the trial due to lack of efficacy

Conditions

• Non-CNS Tumor

Interventions

• BIOLOGICAL: GEN1042
• DRUG: Pembrolizumab
• RADIATION: Radiotherapy

Sponsor

Genmab

Collaborators

• [object Object]